Clinical trials: Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).
This multicenter, open-label, single arm, interventional, long-term extension (LTE) study will evaluate the safety and efficacy of tocilizumab (TCZ, RoActemra/Actemra) in French participants with moderate to severe RA who have…
- Trial name
- NCT01734993
- Testing
- Tocilizumab
- Where
- 6 sites in France
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving but not fully responding to treatment with methotrexate…
- Trial name
- CREDO 2 (NCT02760407)
- Testing
- Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 1,648 people
- Sponsor
- R-Pharm International, LLC
Rheumatoid Arthritis
A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.
A multi-center, open-label single-arm study to evaluate the efficacy and safety of tocilizumab administered as a single, weekly injection in adults with rheumatoid arthritis.
- Trial name
- NCT01988012
- Testing
- tocilizumab
- Where
- 13 sites in Israel
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab
This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable…
- Trial name
- NCT02792699
- Testing
- ABP 798, Rituximab (US), Rituximab (EU)
- Where
- 55 sites in United States, Bulgaria and 4 more
- Volunteers
- 311 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)
This Phase 3, randomized, open-label, multicenter study in rheumatoid arthritis (RA) patients with low disease activity (Disease Activity Score 28 [DAS28] >2.8 and <3.5) is being conducted to evaluate induction of remission by…
- Trial name
- NCT00521924
- Testing
- infliximab, DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Rheumatoid
Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA
Prospective, open-label, multicenter, dose escalation, safety with pharmacokinetics (PK) and dosimetry study of injected Tc 99m tilmanocept in the detection of and assessment of localization to skeletal joints in subjects with…
- Trial name
- NCT02865434
- Testing
- Tc99m-tilmanocept, SPECT Imaging (60 Minutes post-injection), SPECT Imaging (180 Minutes post-injection)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Rheumatoid Arthritis
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
The purpose of the study is to better understand the factors present in the cells of inflamed joints of patients with arthritis that may cause rheumatoid arthritis.
- Trial name
- NCT02451748
- Testing
- Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Illinois Chicago
Rheumatoid Arthritis
A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
This is a phase III, randomized, controlled, double-blind, parallel group, international study in approximately 750 patients with active Rheumatoid Arthritis (RA) who are naive to Methotrexate (MTX) therapy.
- Trial name
- IMAGE (NCT00299104)
- Testing
- folate, methotrexate, methylprednisolone
- Volunteers
- 755 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis (RA)
Use of Acthar in Rheumatoid Arthritis (RA) Related Flares
This is a Rheumatoid Arthritis (RA) study. The purpose of this research study is to determine in RA flare, whether musculoskeletal ultrasound (MSUS) inflammatory scores and/or disease activity scores improve with Acthar treatment.
- Trial name
- NCT02541955
- Testing
- Acthar
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Veena Ranganath, MD, MS
Rheumatoid Arthritis
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis
The purpose of this study is to assess whether DCE-MRI can detect changes of active disease in rheumatoid arthritis (RA) patients after 4, 8 and 12 weeks of etanercept.
- Trial name
- NCT00361634
- Testing
- Etanercept
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 14 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis (RA)
Evaluation of Health Related Quality of Life (HRQL) is of a paramount importance in assessing the impact of rheumatoid arthritis on patients' health status, however when costs associated with rheumatoid arthritis are also taken…
- Trial name
- HEOR (NCT01078116)
- Where
- 10 sites in Greece
- Volunteers
- 124 people
- Sponsor
- Abbott
Rheumatoid Arthritis
A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate
The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis while on a background treatment of methotrexate.
- Trial name
- FLEX M (NCT01198002)
- Testing
- LY2127399, Methotrexate
- Where
- 234 sites in United States, Argentina and 21 more
- Volunteers
- 1,041 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
Primary Objective: To document the long-term safety of sarilumab added to non-methotrexate (non-MTX) disease-modifying antirheumatic drugs (DMARDs) or as monotherapy.
- Trial name
- NCT02373202
- Testing
- Sarilumab, Sulfasalazine, Leflunomide
- Where
- 40 sites in Japan
- Volunteers
- 91 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
A Study in Participants With Rheumatoid Arthritis
The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis in participants with an inadequate response to one or more tumor necrosis factor-alpha (TNF-α)…
- Trial name
- FLEX V (NCT01202773)
- Testing
- LY2127399
- Where
- 201 sites in United States, Argentina and 17 more
- Volunteers
- 456 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
The objectives of Period 1 were the following: To compare the safety and efficacy of upadacitinib 7.5 mg once daily (QD) monotherapy (for participants in Japan only), 15 mg QD monotherapy, and 30 mg QD monotherapy versus weekly…
- Trial name
- SELECT-EARLY (NCT02706873)
- Testing
- Methotrexate, Upadacitinib
- Where
- 290 sites in United States, Argentina and 43 more
- Volunteers
- 1,002 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
This is a randomized, double-blind study comparing ABT-494 to placebo in Japanese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying…
- Trial name
- SELECTSUNRISE (NCT02720523)
- Testing
- Upadacitinib
- Where
- 50 sites in Japan
- Volunteers
- 197 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Psoriatic Arthritis
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is an inflammatory form of arthritis that causes joint pain and damage. RA attacks the lining of the joints (synovium), causing swelling that can result in aching and throbbing, and eventually deformity.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Periodontal Disease
- Trial name
- NCT01198509
- Testing
- doxycycline, vancomycin
- Where
- 2 sites in United States
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Rheumatoid Arthritis
A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.
This open-label, single arm study will assess the effect of RoActemra/Actemra (tocilizumab) on neutrophils and monitor safety and benefit-risk of RoActemra/Actemra treatment in patients with active rheumatoid arthritis who have…
- Trial name
- NCT01195272
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study in Patients With Rheumatoid Arthritis
The primary purpose of the study is to help answer the following research questions, and not to provide treatment for Rheumatoid Arthritis (RA): The safety of LY2439821 and any side effects that might be associated with it.
- Trial name
- NCT00966875
- Testing
- LY2439821
- Where
- 75 sites in United States, Argentina and 9 more
- Volunteers
- 448 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
This randomized, double-blind, placebo-controlled study will compare the efficacy with regard to sustained remission and safety of tocilizumab and methotrexate, in combination or as monotherapy, in treatment-naïve patients with…
- Trial name
- NCT01034137
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 21 sites in Netherlands
- Volunteers
- 317 people
- Sponsor
- Hoffmann-La Roche